Dr. Mustafa al’Absi, professor and licensed psychologist, recently published his findings in the International Review of Neurobiology looking at the long-term effects of stress and early-life adversity on addiction.
Ricardo Battaglino, PhD, in the Department of Rehabilitation Medicine, teamed up with fellow U colleagues to study the use of apilimod in treating COVID-19. Early results, using cell culture work, show that the drug is five times more effective than remdesivir.
Forum Kamdar, MD, FACC, in the Department of Medicine is one of 17 physician scientists in the U.S. to receive a $495,000 award from the Doris Duke Charitable Foundation to expand on her research that hopes to improve therapy for those with Duchenne muscular dystrophy.
Mohamed Hassan, MD, FAASLD, a professor in the Department of Medicine, discusses his research on Hepatitis B virus—a type of viral hepatitis that disproportionately impacts the immigrant population in the Twin Cities.
Jean Regal, PhD, in the Department of Biomedical Sciences and Emilyn Alejandro, PhD, from the Department of Integrative Biology and Physiology, team up for a first-of-its-kind research project to examine the development of Type 2 diabetes in offspring of hypertensive pregnancies.
Stanley Thayer, PhD, in the Department of Pharmacology helped narrow in on a potential drug target that rescues synaptic connections and restores cognitive function in patients with HIV-associated neurocognitive disorders.
Janna Gewirtz O’Brien, MD, FAAP, a fellow in the Department of Pediatrics, leads a team in a secondary data analysis of Minnesota youth. The findings suggest that primary care could act as a point of intervention for youth with unstable housing situations.
First randomized clinical trial of hydroxychloroquine to treat non-hospitalized adults with COVID-19.
Elizabeth Bradley, PhD, in the Department of Orthopedic Surgery studies the mechanisms that regulate age-related bone changes in women, focusing on protein phosphatase and enzyme histone deacetylase.
Geoffrey Hart, PhD, in the Department of Medicine, and Marco Pravetoni, PhD, in the Department of Pharmacology, teamed up to develop a universal vaccine and monoclonal antibodies to protect against SARS-CoV-2 (COVID-19) and future emerging strains.